SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joseph wang who wrote (48)8/20/1996 8:23:00 PM
From: Tara Cobble   of 1154
 
Fellow GENE shareholders a little more information for the hungry few. Last night I happened to receive my Semi-Annual report from Acorn Fund and Acorn International. You all may know that Acorn Fund is a very well know fund managed by Ralph Wanger a very prominent investment manager. Anyway the Acorn Fund has been a very good performing fund with the following return data 2nd qtr 7%, last 6 months 15.2%, last 12 months 24.8%, 5 year avg. 20.3%, 10 year avg. 15%, and over the life of the fund 16.8%. Anyway now after that long speil, I was perusing the 2nd quarter changes in the fund (3/31/96 - 6/30/96) and on page 8 under Health Care additions was our very own GENOME THERAPEUTICS 200,000 shares.

Looking at a chart it would appear over that time frame GENE trading range was from a high around 11.75 to a low of 8.4. So anyway the Acorn Fund has 200,000 shares of GENE at some price between that range.
As you also know the volume has been realtively flat the last 3 months with only 4 to 5 spikes which the volume has been picking up lately. In mid July (during the correction in the market) GENE hit its 52 week low of 6 and today is currently around 8 7/8 moving up only recently from 7. Bottom line if you didn't dollar cost average down over the last month you may still have some time even with the current move up and I feel very very comfortable being in a stock that Ralph Wanger has in his portfolio. GENE will definately be a winner, not only short term (1 to 2 years) but also for those willing to hold for the longer run. (just my opinion)
Good Luck Tara
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News